Boston Scientific third-quarter 2026 financial results
Boston Scientific reported financial results for the third quarter of 2026, which ended September 30. The company's net sales for this period were $5,138 million.
Key points
- In the third quarter of 2026, Boston Scientific reported net sales of $5,138 million and a gross profit of $3,428 million.
- The company recognized a financial benefit related to the recovery of previously incurred tariffs imposed under the International Emergency Economic Powers Act (IEEPA).
- Boston Scientific notes several factors that may affect future operating results.
Quarterly financial highlights
In the third quarter of 2026, Boston Scientific reported net sales of $5,138 million and a gross profit of $3,428 million. The company's operating income for the quarter reached $828 million, with net income of $580 million.
Revenue by quarter, $B
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
Financial impact of tariff recovery
The company recognized a financial benefit related to the recovery of previously incurred tariffs imposed under the International Emergency Economic Powers Act (IEEPA). This benefit was recorded as a reduction in the cost of products sold in the statement of operations.
Operating risk factors
Boston Scientific notes several factors that may affect future operating results. These include global political, competitive, and regulatory conditions, changes in trade and tariff policies, supply chain disruptions, and potential disruptions caused by cybersecurity events, including the one first reported on August 26, 2026.
Further results reporting
The impact of such factors on the company's future operations is generally reflected in reports for subsequent periods.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Boston Scientific
A notification in your browser or on your phone when we publish about Boston Scientific. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
